Oligonucleotide News and Research

RSS

New drug provides hope for patients with Duchenne muscular dystrophy

The results from three clinical trials have shown that a new drug can successfully delay the progression of Duchenne muscular dystrophy.

10 Jul 2019

IDT and 3CR team up to widen access to custom solutions for genotyping screening

In the latest collaboration in a series to advocate for genomics research, Integrated DNA Technologies is teaming up with 3CR Bioscience to widen access to quality custom solutions for genotyping screening.

From Integrated DNA Technologies 3 Jul 2019

Scientists aim to develop new ointment that could reduce risks of primary skin cancer

Scientists from Far Eastern Federal University, V.I. Vernadsky Crimean Federal University, Dmitry Mendeleev University of Chemical Technology, and Far Eastern Branch of the Russian Academy of Sciences, assumed the risks of primary skin cancer and its recurrences can be significantly reduced by applying the ointment with antisense oligonucleotides which are short DNA, RNA fragments used in oncology to suppress the synthesis of tumor proteins.

3 Jul 2019

Vanderbilt investigators discover link between vascular biology and eye disease

In a series of studies that volleyed between large databases and research in zebrafish, Vanderbilt investigators have discovered a link between vascular biology and eye disease.

25 Apr 2019

Scientists present a new approach to fight cancer

In recent years, it's become clear that RNA-binding proteins play a major role in cancer growth. These proteins, active in all cells but especially so in cancer cells, bind to RNA molecules and accelerate cancer cell growth.

15 Apr 2019

Cloning-free Nested CRISPR uses long DNA fragments for efficient gene editing

CRISPR is a technique that is revolutionizing biomedical research through high-precision genome editing. However, even though it allows the creation or correction of mutations consisting of a single or few nucleotides with relative ease, it still possesses limitations upon introducing larger fragments of DNA in the genome.

8 Feb 2019

New class of antisense oligonucleotide therapeutics tested in humans

A first-in-human study with a new class of antisense oligonucleotide therapeutics showed the ability to target the RNA-silencing drug to the liver, resulting in improved potency and safety at therapeutic doses. The design and results of this trial, conducted in healthy human volunteers are reported in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

28 Jan 2019

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney.

From AstraZeneca 10 Jan 2019

New therapy for childhood blindness shows 'very promising' results

A new therapy aimed at improving the sight of people with one of the most common forms of childhood blindness, has shown 'very promising' initial results, according to a study involving UCL researchers.

18 Dec 2018

Intraocular injection improves vision in a form of congenital retinal blindness

A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.

18 Dec 2018

New mouse model shows potential for rapid identification of promising muscular dystrophy therapies

A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.

13 Dec 2018

New form of therapy may stop or reverse progressive vision loss

A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness.

1 Nov 2018

IDT to demonstrate CRISPR expertise at European-focused events

As an advocate for the genomics age, Integrated DNA Technologies (IDT), will showcase its renowned CRISPR expertise at a series of European-focused events.

From Integrated DNA Technologies 22 Oct 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

Researchers develop two-pronged approach for targeting Ebola virus

In a new study researchers have developed a two-pronged approach for targeting Ebola virus infection using linked nucleic acid (LNA) antisense oligonucleotides (ASOs)designed to interfere both genes essential for translation of Ebola virus genes and to block production of an intracellular human protein needed for the virus to enter cells.

12 Oct 2018

Krembil scientists develop potential treatment to stop knee and spine osteoarthritis

Scientists at the Krembil Research Institute have developed a novel therapeutic treatment that has the potential to stop knee and spine osteoarthritis in its tracks.

5 Oct 2018

Study: Reducing mutated Huntington disease protein restores psychiatric impairments in mice

New research from the University of British Columbia suggests that reducing mutated Huntington disease protein in the brain can restore cognitive and psychiatric impairments in mice.

4 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

MDA announces 34 new grants totaling $9.9 million to accelerate neuromuscular research

The Muscular Dystrophy Association today announced the award of 34 new grants totaling more than $9.9 million for its summer round of funding. These new grants represent a continued commitment by MDA to fund groundbreaking research that will accelerate treatments and cures for the more than 40 diseases in its program.

24 Aug 2018

Scientists create new tool to precisely control 3D architecture of linkages in drugs

When it comes to certain molecules, shape makes all the difference. The shape of limonene, for instance, a compound produced by citrus fruits, determines whether it tastes like orange juice or turpentine.

7 Aug 2018